Published in Arch Immunol Ther Exp (Warsz) on January 01, 1997
Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS One (2010) 0.92
Therapeutic drug monitoring of immunosuppressant drugs. Br J Clin Pharmacol (1999) 0.83
Efficacy and comparative effectiveness of sirolimus as an anticancer drug. Laryngoscope (2011) 0.82
Pharmacological Modulation of Photoreceptor Outer Segment Degradation in a Human iPS Cell Model of Inherited Macular Degeneration. Mol Ther (2015) 0.79
Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature (1999) 6.42
Multiple dynamic representations in the motor cortex during sensorimotor learning. Nature (2012) 3.03
Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc Natl Acad Sci U S A (1998) 3.02
Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J (2009) 2.82
Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood (2001) 2.73
Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro (1976) 2.65
The impact of comorbid and sociodemographic factors on access to renal transplantation. JAMA (1993) 2.54
Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation. Proc Natl Acad Sci U S A (1998) 2.22
Salt extraction of soluble HL-A antigens. Science (1971) 2.18
Functional contributions of alpha5 subunit to neuronal acetylcholine receptor channels. Nature (1996) 2.06
KCNE1 mutations cause jervell and Lange-Nielsen syndrome. Nat Genet (1997) 1.90
Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation (1985) 1.83
Regularized estimation for the accelerated failure time model. Biometrics (2009) 1.80
Transplantation antigens. Adv Immunol (1970) 1.70
Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics (1997) 1.68
Indoor coal combustion emissions, GSTM1 and GSTT1 genotypes, and lung cancer risk: a case-control study in Xuan Wei, China. Cancer Epidemiol Biomarkers Prev (2000) 1.59
Calibrating parametric subject-specific risk estimation. Biometrika (2010) 1.54
Quinone-induced oxidative stress elevates glutathione and induces gamma-glutamylcysteine synthetase activity in rat lung epithelial L2 cells. J Biol Chem (1994) 1.53
En bloc transplantation of kidneys from pediatric donors. J Urol (1996) 1.51
The synergistic effects of cyclosporine and sirolimus. Transplantation (1997) 1.47
Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc (1988) 1.44
Ranitidine, cimetidine, and the cyclosporine-treated recipient. Transplantation (1986) 1.44
Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol (1997) 1.43
Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Transplantation (1999) 1.42
Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via In utero or postnatal transfer. Blood (1998) 1.41
Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med (2000) 1.41
Functional analysis of HD2 histone deacetylase homologues in Arabidopsis thaliana. Plant J (2000) 1.41
HLA matching assessed from early graft function. Transplant Proc (1987) 1.40
Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation (1998) 1.36
Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet (2001) 1.36
Alterations in rat pulmonary macrophage function by the immunosuppressive agents cyclosporine, azathioprine, and prednisolone. Transplantation (1983) 1.35
On estimating medical cost and incremental cost-effectiveness ratios with censored data. Biometrics (2001) 1.33
Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion. Oncogene (2011) 1.32
VDR and NRAMP1 gene polymorphisms in susceptibility to pulmonary tuberculosis among the Chinese Han population: a case-control study. Int J Tuberc Lung Dis (2004) 1.32
Immunopharmacological monitoring of cyclosporin A-treated recipients of cadaveric kidney allografts. Transplantation (1982) 1.28
Sp1-binding elements in the promoter of RAGE are essential for amphoterin-mediated gene expression in cultured neuroblastoma cells. J Biol Chem (1998) 1.27
Binding of cyclosporine by human lymphocytes and phospholipid vesicles. J Immunol (1983) 1.26
Functional analysis of a RPD3 histone deacetylase homologue in Arabidopsis thaliana. Plant Mol Biol (2000) 1.26
The impact of HLA mismatches on the survival of first cadaveric kidney transplants. N Engl J Med (1994) 1.26
De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery (1985) 1.24
Partial artificial heart (ALVAD) use with subsequent cardiac and renal allografting in a patient with stone heart syndrome. Artif Organs (1978) 1.23
Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol Cell Biol (2001) 1.23
Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant (2009) 1.22
Violence, alcohol, and completed suicide: a case-control study. Am J Psychiatry (2001) 1.19
Biological and chemical characterization of human histocompatibility antigens. Fed Proc (1971) 1.19
Leukocyte integrins and inflammation. Cell Mol Life Sci (1998) 1.19
Transplantaton antigens. Science (1969) 1.18
Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation (2000) 1.18
Epigenetic inactivation of T-box transcription factor 5, a novel tumor suppressor gene, is associated with colon cancer. Oncogene (2010) 1.17
Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol (2001) 1.17
Genome-wide association identifies SKIV2L and MYRIP as protective factors for age-related macular degeneration. Genes Immun (2010) 1.16
Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci U S A (2001) 1.14
Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol (2000) 1.14
Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. Transplantation (1987) 1.13
Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation (1991) 1.12
Mutations that cause the Wiskott-Aldrich syndrome impair the interaction of Wiskott-Aldrich syndrome protein (WASP) with WASP interacting protein. J Immunol (1999) 1.11
Activation of acyl-coenzyme A:cholesterol acyltransferase by cholesterol or by oxysterol in a cell-free system. J Biol Chem (1995) 1.09
Can an immunologically, nonreactive potential allograft recipient undergo transplantation without a donor-specific crossmatch? Transplantation (1998) 1.09
New approaches to cyclosporine monitoring raise further concerns about analytical techniques. Clin Chem (2000) 1.07
Characterization of Candida albicans RNA triphosphatase and mutational analysis of its active site. Nucleic Acids Res (2000) 1.07
DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br J Cancer (2009) 1.07
Analysis of carotenoid biosynthetic gene expression during marigold petal development. Plant Mol Biol (2001) 1.06
The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int (1996) 1.06
DDX5 is a positive regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic leukemia. Oncogene (2012) 1.06
Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients. Oncogene (2011) 1.06
Sequential determinations of serum interleukin 6 levels as an immunodiagnostic tool to differentiate rejection from nephrotoxicity in renal allograft recipients. Transplantation (1991) 1.05
Induction of apoptosis by norcantharidin in human colorectal carcinoma cell lines: involvement of the CD95 receptor/ligand. J Cancer Res Clin Oncol (2002) 1.05
Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther (1993) 1.05
Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br J Pharmacol (2009) 1.04
Isolation, sequencing, and mapping of the human homologue of the yeast transcription factor, SPT5. Genomics (1996) 1.04
Clinicopathological correlations of disseminated intravascular coagulation in patients with head injury. Neurosurgery (1984) 1.04
Human colon adenocarcinoma cells. II. Tumorigenic and organoid expression in vivo and in vitro. J Natl Cancer Inst (1977) 1.03
Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem (1996) 1.02
Calf sonography for detecting deep venous thrombosis in symptomatic patients: experience and review of the literature. J Clin Ultrasound (1999) 1.02
A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther (2002) 1.02
Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy (1998) 1.01
Cyclosporine: the agent and its actions. Transplant Proc (1985) 1.01
Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue. Mol Pharmacol (1999) 1.01
New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets (2010) 1.00
Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. Transplantation (1999) 1.00
Enhancers and core promoter elements are essential for the activity of a cryptic gene activation sequence from tobacco, tCUP. Mol Genet Genomics (2001) 0.99
Molecular components of large conductance calcium-activated potassium (BK) channels in mouse pituitary corticotropes. Mol Endocrinol (1999) 0.99
Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. Transplantation (2001) 0.98
BDCA-1+, BDCA-2+ and BDCA-3+ dendritic cells in early human pregnancy decidua. Clin Exp Immunol (2008) 0.98
Differential expression of microRNAs during allograft rejection. Am J Transplant (2012) 0.98
Specific tumor immunity induced with soluble materials: restricted range of antigen dose and of challenge tumor load for immunoprotection. J Immunol (1975) 0.98
Distribution of sirolimus in rat tissue. Clin Biochem (1997) 0.97
Evaluating subject-level incremental values of new markers for risk classification rule. Lifetime Data Anal (2013) 0.97
Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens. Transplant Proc (2011) 0.96
Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc (2003) 0.96
Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines. Eur J Cancer (1997) 0.96
Use of cyclosporine in pediatric renal transplant recipients. J Pediatr (1985) 0.95
Serologic methods for the early diagnosis of Pneumocystis carinii infection in renal allograft recipients. Transplantation (1986) 0.95
Quantitation of plasma azathioprine and 6-mercaptopurine levels in renal transplant patients. Transplantation (1980) 0.95
Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for from one to five years. Transplantation (1987) 0.94
Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. Am J Kidney Dis (1999) 0.94
Soluble tumor-specific transplantation antigens from methylcholanthrene-induced guinea pig sarcomas. Cancer (1970) 0.94
Cyclosporin A: a selective anti-T cell agent. Clin Haematol (1982) 0.94